Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the completion of the dose escalation stage of VS-6063 and paclitaxel in a Phase 1/1b trial in patients with ovarian cancer.
http://www.businesswire.com/news/topix/20130627005619/en
http://www.businesswire.com/news/topix/20130627005619/en
No comments:
Post a Comment